p.136 抽出テキスト

open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial”. Am Heart J 2017; 188: 11–17. PMID: 28577666 938. Nakamura M, Iijima R, Ako J, et al. NIPPON Investigators. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv 2017; 10: 1189–1198. PMID: 28641838 939. Harjai KJ, Shenoy C, Orshaw P, et al. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 2009; 95: 1579–1586. PMID: 19549619 940. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374–1382. PMID: 20231231 941. Tada T, Natsuaki M, Morimoto T, et al. CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/ CABG Registry Cohort-2. Circ Cardiovasc Interv 2012; 5: 381–391. PMID: 22619260 942. Costa F, van Klaveren D, James S, et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025–1034. PMID: 28290994 943. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016; 315: 1735–1749. PMID: 27022822 944. Kereiakes DJ, Yeh RW, Massaro JM, et al: DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol 2016; 67: 2492–2502. PMID: 27046159 945. Watanabe H, Ozasa N, Morimoto T, et al. CAPITAL-RCT investigators. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One 2018; 13: e0199347. PMID: 30153268 946. Freemantle N, Cleland J, Young P, et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–1737. PMID: 10381708 947. Dondo TB, Hall M, West RM, et al. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol 2017; 69: 2710–2720. PMID: 28571635 948. Noble S, Roffi M. Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue? J Thorac Dis 2017; 9: 4191–4194. PMID: 29268468 949. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102–112. PMID: 15262665 950. Demers C, McMurray JJ, Swedberg K, et al. CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005; 294: 1794-1798. PMID: 16219883 951. Sakamoto T, Ogawa H, Nakao K, et al. 4C (Candesartan for Prevention of Cardiovascular Events after CYPHERTM or TAXUSTM Coronary Stenting) study investigators. Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. J Cardiol 2016; 67: 371–377. PMID: 26254019 952. Werner N, Nickenig G. AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis. Eur Heart J 2003; 5(suppl_A): A9–A13. 953. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068. PMID:15531767 954. Pitt B, O’Neill B, Feldman R, et al. QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058–1063. PMID: 11348602 955. ONTARGET Investigators.Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559. PMID: 18378520 956. Kohro T, Hayashi D, Okada Y, et al. JCAD Investigators. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2007; 71: 1835–1840. PMID: 18037732 957. IONA Study Group. Impact of nicorandil in angina: subgroup

analyses. Heart 2004; 90: 1427–1430. PMID: 15547020 958. Yamauchi T, Hagiwara N, Kasanuki H, et al. Long-term nitrate use in acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology nitrate evaluation program). Cardiovasc Drugs Ther 2008; 22: 177–184. PMID: 18288597 959. Kojima S, Matsui K, Sakamoto T, et al. Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J 2007; 71: 301–307. PMID: 17322625 960. Horinaka S, Yabe A, Yagi H, et al. JCAD Study Investigators. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74: 503–509. PMID: 20081320 961. Kasama S, Toyama T, Sumino H, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011; 97: 20–26. PMID: 21062772 962. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225. PMID: 15536108 963. Mihaylova B, Emberson J, Blackwell L, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590. PMID: 22607822 964. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681. PMID: 21067804 965. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381. PMID: 27222591 966. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387–2397. PMID: 26039521 967. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713–1722. PMID: 28304224 968. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316: 2373–2384. PMID: 27846344 969. Tsujita K, Sugiyama S, Sumida H, et al. PRECISE–IVUS Investigators. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015; 66: 495–507. PMID: 26227186 970. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016; 316: 1289–1297. PMID: 27673306 971. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015; 13: 123. PMID: 26099511 972. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509. PMID: 25773607 973. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-1499. PMID: 25773378 974. Thomopoulos C, Skalis G, Michalopoulou H, et al. Effect of

Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/ Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clin Cardiol